Description

Androfarm (Cyproterone) Tablets 50 mg. №20

Composition

Active Ingredient: Cyproterone 50 mg

Mechanism of Action

Cyproterone acts as an androgen receptor antagonist, inhibiting the effects of androgens in the body. By blocking androgen receptors, cyproterone helps reduce symptoms of hyperandrogenism such as hirsutism and acne.

Pharmacological Properties

Androfarm containing cyproterone is indicated for the treatment of hirsutism, acne, androgenetic alopecia, and other androgen-dependent conditions in women.

Detailed Indications for Use

Androfarm is recommended for the treatment of hirsutism, acne, androgenetic alopecia, and other androgen-dependent conditions in women.

Contraindications

Avoid using Androfarm if pregnant, breastfeeding, or have liver disease. Consult a healthcare provider before use.

Side Effects

Common side effects may include nausea, breast tenderness, and mood changes. Contact a healthcare provider if severe side effects occur.

Usage Instructions

Take 50 mg of Androfarm once daily as directed by a healthcare provider. Swallow the tablet whole with a full glass of water.

Benefits Compared to Analogues

Androfarm has shown efficacy in reducing hirsutism and improving acne in women with hyperandrogenism. Comparative studies suggest similar effectiveness to other anti-androgen medications with potentially fewer side effects.

Suitable Patient Groups

Androfarm is suitable for adult women with hirsutism, acne, androgenetic alopecia, and other androgen-dependent conditions.

Storage Conditions and Shelf Life

Store Androfarm in a cool, dry place away from sunlight. Check the expiration date on the packaging and do not use expired tablets.

Packaging Description

Androfarm is available in packages containing 20 tablets of 50 mg each.

Clinical Evidence and Proven Effectiveness

Androfarm containing cyproterone has been studied for its efficacy in treating hyperandrogenism-related conditions in women. Research has shown its effectiveness in reducing hirsutism and improving acne in women with polycystic ovary syndrome.